JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Thompson, K. A.
Right arrow Articles by Roden, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thompson, K. A.
Right arrow Articles by Roden, D. M.

Comparative in vitro electrophysiology of quinidine, its major metabolites and dihydroquinidine

KA Thompson, IA Blair, RL Woosley and DM Roden

Although metabolites of quinidine are active in animal models and can accumulate to plasma levels similar to those of quinidine during chronic therapy, their effects on cardiac transmembrane action potentials have not been reported. We therefore examined the effects of quinidine, its major metabolites, 3-hydroxyquinidine, quinidine-N- oxide, O-desmethylquinidine, and 2'-oxoquinidinone, and a common commercial impurity, dihydroquinidine, on action potentials from canine Purkinje fibers. Using standard microelectrode techniques, measurements at stimulation basic cycle lengths (BCLs) of 300 to 8000 msec were made at base line and repeated after a 1 hr of superfusion with a 10 microM concentration of drug or vehicle controls. Vehicle controls (n = 5) produced no change in maximum phase 0 upstoke slope of the action potential (Vmax) or action potential duration at 90% repolarization (APD90). Vmax depression when present was greatest at short BCL with statistically significant changes seen at BCL = 300 msec with all compounds tested except quinidine-N-oxide. The time constants for the onset of and recovery from frequency-dependent Vmax depression were similar to those of quinidine. In contrast, changes in APD90 were greatest at long BCL, with significant prolongation seen with all drugs at BCL = 4000 msec. In addition, the agents prolonging repolarization to the greatest extent, quinidine, dihydroquinidine, 3-hydroxyquinidine and O-desmethylquinidine, caused early afterdepolarizations at long BCL. We conclude that these metabolites and dihydroquinidine may contribute to the antiarrhythmic and/or arrhythmogenic effects of quinidine therapy.

Volume 241, Issue 1, pp. 84-90, 04/01/1987
Copyright © 1987 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
M. F. Fromm, D. Darbar, S. Dell'Orto, and D. M. Roden
Modulation of Effect of Dietary Salt on Prehepatic First-Pass Metabolism: Effects of beta -Blockade and Intravenous Salt Loading
J. Pharmacol. Exp. Ther., July 1, 1999; 290(1): 253 - 258.
[Abstract] [Full Text]


Home page
NEJMHome page
A. A. Grace and A. J. Camm
Quinidine
N. Engl. J. Med., January 1, 1998; 338(1): 35 - 45.
[Full Text] [PDF]


Home page
CirculationHome page
E. A. Sosunov, E. P. Anyukhovsky, and M. R. Rosen
Effects of Quinidine on Repolarization in Canine Epicardium, Midmyocardium, and Endocardium : I. In Vitro Study
Circulation, December 2, 1997; 96(11): 4011 - 4018.
[Abstract] [Full Text]


Home page
CirculationHome page
B. S. Koller, P. E. Karasik, A. J. Solomon, and M. R. Franz
Relation Between Repolarization and Refractoriness During Programmed Electrical Stimulation in the Human Right Ventricle : Implications for Ventricular Tachycardia Induction
Circulation, May 1, 1995; 91(9): 2378 - 2384.
[Abstract] [Full Text]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1987 by the American Society for Pharmacology and Experimental Therapeutics.